Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;33(1):109-111.
doi: 10.1016/j.annonc.2021.10.004. Epub 2021 Oct 20.

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

J C Figueiredo  1 , U Ihenacho  2 , N M Merin  3 , O Hamid  4 , J Darrah  3 , J Gong  3 , R Paquette  3 , A C Mita  3 , R Vescio  3 , I Mehmi  3 , R Basho  3 , S J Salvy  3 , C H Shirazipour  5 , N Caceres  3 , L J Finster  3 , B Coleman  6 , H U Arnow  6 , L Florindez  6 , K Sobhani  3 , J C Prostko  7 , E C Frias  7 , J L Stewart  7 , A Merchant  3 , K L Reckamp  8
Affiliations

SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

J C Figueiredo et al. Ann Oncol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure JG holds a consultant or advisory role at EMD Serono; Elsevier; Exelixis; QED Therapeutics; Natera, Basilea, HalioDx, Eisai, Janssen. KLR holds a consultant or advisory role at Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Genentech, GSK, Janssen, Lilly, Merck KGA, Mirati, Seattle Genetics, Takeda. JD holds a consultant or advisory role at Kite Pharma and MorphoSys. RB holds a consultant or advisory role at Genomic Health, Astra Zeneca, Biotheranostics, Pfizer; she is on the Speakers Bureau for Genentech, Seattle Genetics; she also has research funding from Seattle Genetics, Ichnos Biosciences, Merck. All other authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Acute side-effects after vaccination among patients with cancer by (A) Sex: male versus female. (B) Cancer type: solid versus hematologic malignancies. (C) Treatment: B-cell targeted therapy (BCT) versus no BCT. (D) Treatment: immune checkpoint inhibitors (ICI) versus no ICI. (E) Treatment: hormone therapy (HT) versus no HT. (F) Treatment: cytotoxic chemotherapy (CT) versus no CT.
See this image and copyright information in PMC

References

    1. Barriere J., Gal J., Hoch B., et al. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021;32:673–674. - PMC - PubMed
    1. Waissengrin B., Agbarya A., Safadi E., et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22:581–583. - PMC - PubMed
    1. Domek G.J., O’Leary S.T., Bull S., et al. Measuring vaccine hesitancy: field testing the WHO SAGE Working Group on Vaccine Hesitancy survey tool in Guatemala. Vaccine. 2018;36:5273–5281. - PMC - PubMed
    1. Luo B., Li J., Hou X., et al. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination. Future Oncol. 2021;17:3477–3484. - PMC - PubMed
    1. Maio M., Hamid O., Larkin J., et al. Immune checkpoint inhibitors for cancer therapy in the COVID-19 era. Clin Cancer Res. 2020;26:4201–4205. - PubMed

Publication types

Substances